MedTrace Logo

A Phase II Study of Sintilimab, Pegaspargase and Selinexor Followed by Radiotherapy in Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma

NCT07574528 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2026-05-08

No results posted yet for this study

Summary

This is a single-arm, open-label, multicenter phase II study evaluating sintilimab, pegaspargase, and selinexor followed by radiotherapy as first-line treatment for patients with newly diagnosed stage I/II extranodal natural killer/T-cell lymphoma (ENKTL).

Conditions

  • NKTCL

Interventions

DRUG

Sintilimab

Sintilimab will be given at 200 mg by intravenous infusion.

DRUG

Pegaspargase

Pegaspargase will be given at 2000 U/m², with a maximum total dose of 3750 U, by intramuscular injection.

DRUG

Selinexor

Selinexor will be given orally once weekly at 60mg.

RADIATION

radiotherapy

Patients will receive induction treatment for up to 4 cycles, followed by radiotherapy.

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-06
Primary Completion
2028-03-06
Completion
2031-05-06

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07574528 on ClinicalTrials.gov